Top Back to top

High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis

Study number:
2006-004598-83
Type of transplant:
 
Short title:
ASTIS
Study status:
Completed Patient Recruitment
Deadline for data collection:
 
Study design:
Multicentre, randomised, controlled trial
Primary objective:
To evaluyate the potential clinical benefit of high dose immunoablation and autologous stem cell transplantation in comparison to intravenous pulse therapy cyclophosphamide, with respect to survival and prevention of major organ failure, safety, impact on skin thickening, visceral involvement, functional status and quality of life.
Key inclusion criteria:
18-65 years
Country:
Austria
Belgium
Canada
France
Germany
Greece
Italy
Netherlands
Switzerland
United Kingdom
Principal investigator:
J.M. van Laar
Principal investigator email:
 
EBMT Study coordinator:
Ruzena Uddin

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org